MQS Management LLC Buys New Holdings in Zimmer Biomet Holdings, Inc. $ZBH

MQS Management LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 5,376 shares of the medical equipment provider’s stock, valued at approximately $490,000.

Several other hedge funds have also bought and sold shares of ZBH. Ameriprise Financial Inc. lifted its stake in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after purchasing an additional 1,488,918 shares during the last quarter. Nuveen LLC acquired a new stake in Zimmer Biomet in the 1st quarter valued at about $155,891,000. Alyeska Investment Group L.P. acquired a new stake in Zimmer Biomet in the 1st quarter valued at about $101,294,000. Finally, Dodge & Cox lifted its stake in Zimmer Biomet by 2.3% in the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after purchasing an additional 446,018 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Evercore ISI cut their target price on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research note on Tuesday, October 7th. BTIG Research raised their price objective on shares of Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Raymond James Financial raised their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Finally, Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $111.94.

Zimmer Biomet Trading Down 0.0%

Shares of ZBH stock opened at $103.14 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The firm has a 50 day moving average price of $101.86 and a two-hundred day moving average price of $97.68. The company has a market capitalization of $20.43 billion, a PE ratio of 25.09, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. During the same period last year, the firm earned $2.01 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.39% of the stock is owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.